Benitec Biopharma (BNTC) Enterprise Value (2019 - 2025)

Benitec Biopharma has reported Enterprise Value for 7 years, with the latest figure at -$188.9 million in Q4 2025.

• Quarterly Enterprise Value fell 141.11% year-over-year to -$188.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$188.9 million (down 141.11% YoY) and the FY2025 annual result came in at -$97.9 million, down 92.14% from the prior year.
• Enterprise Value declined to -$188.9 million in Q4 2025 per BNTC's latest filing, from -$94.6 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$13000.0 in Q1 2024 and troughed at -$188.9 million in Q4 2025.
• A 5-year average of -$41.9 million and a median of -$18.1 million in 2021 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value surged 99.8% in 2024, then tumbled 796692.31% in 2025.
• Over 5 years, Enterprise Value stood at -$12.3 million in 2021, then increased by 14.42% to -$10.6 million in 2022, then tumbled by 93.23% to -$20.4 million in 2023, then slumped by 284.27% to -$78.3 million in 2024, then plunged by 141.11% to -$188.9 million in 2025.
• According to Business Quant data, Enterprise Value over the past three periods registered -$188.9 million, -$94.6 million, and -$97.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.